Autism Research Unit
Genetics & Genome Biology
Dr. Vorstman was trained in psychiatry and now specializes in child and adolescent psychiatry. Starting in 2001, his research focuses on the study of genotype-phenotype relations in autism and schizophrenia.
He hopes to further insights into the genetic architecture underlying these disorders and to improve methods to measure the associated phenotypes. Working with Professor Martien Kas at the University of Groningen, Dr. Vorstman developed a smartphone application, BeHapp, for the passive monitoring of social and communicative behaviours.
With his research team, Dr. Vorstman studies the relationships between genes and behaviour, in particular, how genetic variants can contribute to neurodevelopmental disorders such as autism, intellectual disability and schizophrenia. Together with his team he initiated a multidisciplinary clinic for children with genetic risk variants associated with a psychiatric or neurodevelopmental outcome. This clinic, called DAGSY (Developmental Assessment of Genetically Susceptible Youth) recently received considerable funding from CIHR and NIMH, allowing the integration of research and clinical service.
His ambition is to further insights into the genetic architecture underlying neurodevelopmental disorders as well as to improve methods to measure the associated phenotypes. Regarding the latter, he developed a smartphone application, in equal partnership with Professor Kas, which allows 24/7 objective registrations of social and communicative behaviours of individuals. This application, BeHapp, has received substantial funding and is at present implemented in several ongoing studies generating the first data of this kind.
- Schaaf CP, Betancur C, Yuen RKC, Parr JR, Skuse DH, Gallagher L, Bernier RA, Buchanan JA, Buxbaum JD, Chen CA, Dies KA, Elsabbagh M, Firth HV, Frazier T, Hoang N, Howe J, Marshall CR, Michaud JL, Rennie O, Szatmari P, Chung WK, Bolton PF, Cook EH, Scherer SW, Vorstman JAS: A framework for an evidence-based gene list relevant to autism spectrum disorder. Nature reviews Genetics 2020;21:367-376.
- Jongs N, Jagesar R, van Haren NEM, Penninx B, Reus L, Visser PJ, van der Wee NJA, Koning IM, Arango C, Sommer IEC, Eijkemans MJC, Vorstman JA, Kas MJ: A framework for assessing neuropsychiatric phenotypes by using smartphone-based location data. Transl Psychiatry 2020;10:211.
- Vorstman JAS, Olde Loohuis LM, Investigators G, Kahn RS, Ophoff RA, investigators G: Double hits in schizophrenia.Human molecular genetics 2018;27:2755-2761.
- Vorstman JAS, Parr JR, Moreno-De-Luca D, Anney RJL, Nurnberger JI, Jr., Hallmayer JF: Autism genetics: opportunities and challenges for clinical translation. Nature reviews Genetics 2017;18:362-376.
- Vorstman JA, Breetvelt EJ, Duijff SN, Eliez S, Schneider M, Jalbrzikowski M, Armando M, Vicari S, Shashi V, Hooper SR, Chow EW, Fung WL, Butcher NJ, Young DA, McDonald-McGinn DM, Vogels A, van Amelsvoort T, Gothelf D, Weinberger R, Weizman A, Klaassen PW, Koops S, Kates WR, Antshel KM, Simon TJ, Ousley OY, Swillen A, Gur RE, Bearden CE, Kahn RS, Bassett AS, International Consortium on Behavior in 22q11.2 Deletion Syndrome: Cognitive decline preceding the onset of psychosis in patients with 22q11.2 deletion syndrome. JAMA psychiatry 2015;72:377-385.
2003–2004: Principal Investigator. “Genetics and Psychopathology in the 22q11 deletion syndrome” (PI)
Dutch Brain Foundation (Nederlandse Hersen Stichting). €25,000
2006: Principal Investigator. “On the role of CNVs in schizophrenia: what about the other allele?” (PI)
NARSAD Young Investigator Award $60,000 (USD)
2007–2008: Co-Applicant. Prefrontal en Hippocampal Glutamate/Glutamine Concentration in Patients with the 22q11.2 Deletion Syndrome, an MR Spectroscopy Study. Dutch Brain Foundation (Nederlandse Hersen Stichting). PI: Therese van Amelsvoort. €25,000
2010: Principal Investigator. “Clinical and Genetic Aspects of Psychosis in the 22q11.2 Deletion Syndrome” (PI)
NARSAD Young Investigator Award $ 60,000 (USD)
2010–2016: Principal Investigator. “On the Role of Copy Number Variants in Autism: What About the Other Allele?” Dutch Brain Foundation (Nederlandse Hersen Stichting). €150,000. Fellowship grant.
2012: Principal Investigator. University of Utrecht, Intensive Workshop Grant. € 5,000
2012–2017: Co-Applicant. IMI: European Autism Interventions: A Multicenter Study for Developing New Medications (EU-AIMS). PI: Murphy, Declan Murphy. €1,761,000
2013–2018: Principal Investigator (co-PI). NIMH: (5U01MH101722-02). PI: Raquel Gur. $12,000,000
This grant covers expenses of genome sequencing and SNP genotyping, and the construction of a dataset to facilitate pooling of phenotype data from the 22 consortium research sites.
2015–2016: Principal Investigator (co-PI). “BeHapp: using the smartphone to longitudinally monitor adolescent social behavior in real life to predict onset of behavioral disorders” UU: Dynamics of Youth. PI: Martien Kas €103,495
2016–2019: Principal Investigator (co-PI). IMI2: Psychiatric Ratings using Intermediate Stratified Markers (PRISM). PI: Martien Kas. €16,500,000
2016–2021: Co-Applicant. “snel beter behandelen” Smartphone based Monitoring and cognition Modification Against Recurrence of Depression (SMARD)Dutch Brain Foundation (Nederlandse Hersen Stichting) Research program. PI: Erik Ruhé. € 300,000
2017–2021: Co-Applicant. “Language impairment in the 22q11.2 deletion syndrome: a model for SLI?”. NWO (Dutch Science Association). PI: Frank Wijnen. €750,000
2018–2019; Principal Investigator. “A Novel Approach Towards Understanding Social Competence in Paediatric Brain Tumour Survivors”. Psychiatry Endowment Fund Seed Grant Competition, Co-PI: Lai, Meng-Chaun. $30,000 CAD.
2018–2019: Co-Investigator. “Optimized Whole Genome Sequencing Analysis of Complex Disease in a 22q11.2 Deletion Model” McLaughlin Centre Accelerator Grant Competition. PI: Anne Bassett. $50,000 CAD
2018–2019: Co-Investigator. “Whole genome sequencing for stratification in clinical trials in Autism Spectrum Disorder”. McLaughlin Centre Accelerator Grant Competition. PI: Evdokia Anagnostou. $50,000 CAD
2018–2019: Co-Investigator. “Epilepsy Genomics Discovery” McLaughlin Centre Accelerator Grant Competition. PI: Danielle Andrade. $50,000 CAD
2019–2024: Principal Investigator. Early prediction of developmental outcomes: a prospective study of infants with high-impact genetic risk variants. CIHR, $688,500 CAD.
2019–2020: Co-PI. “Paediatric Delirium: Impact on Outcomes and Effect of Systematic Screening”. Psychiatry Endowment Fund Seed Grant Competition. PI: Claire De Souza. $30,000 CAD
2019–2024: Principal Investigator. “Dissecting the effects of genomic variants on neurobehavioral dimensions in CNVs enriched for neuropsychiatric disorders”. National Institutes of Health. $2,667,000 USD.
2020–2023: Principal Investigator. Using smartphone technology for the early detection of bipolar episodes in youth”. Miner’s Lamp Innovation Fund. $150,000 CAD